50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$85.42
-1.14 (-1.32%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$84.00
$87.11
50-Day Range
$86.30
$113.73
52-Week Range
$84.00
$187.29
Volume
350,039 shs
Average Volume
481,596 shs
Market Capitalization
$3.78 billion
P/E Ratio
67.79
Dividend Yield
N/A
Price Target
$149.88

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
75.5% Upside
$149.88 Price Target
Short Interest
Bearish
6.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Omnicell in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$4.29 M Sold Last Quarter
Proj. Earnings Growth
27.31%
From $2.60 to $3.31 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

75th out of 1,069 stocks

Electronic Computers Industry

4th out of 5 stocks

OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Omnicell (NASDAQ:OMCL) PT Lowered to $145.00
Omnicell (NASDAQ:OMCL) Coverage Initiated at KeyCorp
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
8/04/2022
Today
9/26/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,800
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$149.88
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+75.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$77.85 million
Pretax Margin
3.65%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.28 per share
Book Value
$26.09 per share

Miscellaneous

Free Float
43,067,000
Market Cap
$3.78 billion
Optionable
Optionable
Beta
1.06

Social Links


Key Executives

  • Mr. Randall A. LippsMr. Randall A. Lipps (Age 65)
    Founder, Exec. Chairman, Pres & CEO
    Comp: $2.44M
  • Mr. Peter J. KuipersMr. Peter J. Kuipers (Age 50)
    Exec. VP & CFO
    Comp: $1.18M
  • Ms. Christine  MellonMs. Christine Mellon (Age 59)
    Exec. VP, Chief Admin. & People Officer
    Comp: $768.28k
  • Mr. Scott Peter SeidelmannMr. Scott Peter Seidelmann (Age 46)
    Exec. VP & Chief Commercial Officer
    Comp: $1.17M
  • Mr. Joseph Brian SpearsMr. Joseph Brian Spears (Age 62)
    Sr. VP, Chief Accounting Officer & Corp. Controller
  • Mr. Giri Chodavarapu
    Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth
    Sr. VP of Investor Relations
  • Mr. Corey J. Manley
    Sr. VP & Chief Legal Officer
  • Ms. Roxanne Turner
    Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer
  • Mr. Jorge R. Taborga (Age 63)
    Exec. VP of Engineering & Integration Management Officer













OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2022?

8 Wall Street research analysts have issued 1-year target prices for Omnicell's shares. Their OMCL share price forecasts range from $120.00 to $205.00. On average, they predict the company's share price to reach $149.88 in the next twelve months. This suggests a possible upside of 75.5% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2022?

Omnicell's stock was trading at $180.44 at the start of the year. Since then, OMCL shares have decreased by 52.7% and is now trading at $85.42.
View the best growth stocks for 2022 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, August, 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.85 by $0.01. The business earned $331.39 million during the quarter, compared to analyst estimates of $339.45 million. Omnicell had a trailing twelve-month return on equity of 10.37% and a net margin of 4.82%. The business's revenue was up 21.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.71 earnings per share.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY 2025 earnings guidance on Tuesday, September, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.90 billion-$2.00 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.80%), Macquarie Group Ltd. (2.75%), Clearbridge Investments LLC (2.60%), Lazard Asset Management LLC (2.00%), Geneva Capital Management LLC (1.90%) and Price T Rowe Associates Inc. MD (1.11%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $85.42.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $3.78 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.26 on an earnings per share basis.

How many employees does Omnicell have?

The company employs 3,800 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.
Read More
How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.